Award
National Heart, Lung, and Blood Institute 5R01HL167656-04
Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV
Recipient
Oklahoma Medical Research Foundation
Award Amount
$654,015.00
Ceiling
$654,015.00
Awarded
March 06, 2026
Identifier
5R01HL167656-04
NIH awarded a grant to study how antiretroviral therapy drugs contribute to cardiac fibrosis in HIV patients, focusing on platelet activation and TGFβ1 release as mechanisms, with the goal of identifying preventive strategies.
Description
This NIH grant project aims to determine the mechanism and impact of antiretroviral therapy (ART)-induced cardiac fibrosis in people with HIV and explore preventive strategies. The study focuses on the role of platelet-derived TGFβ1 in stimulating macrophages to undergo mesenchymal transition leading to cardiac fibrosis, with specific aims to screen ART classes for platelet TGFβ1 release, determine in vivo effects, and investigate macrophage signaling.